Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients - Phase II study of ramucirumab plus docetaxel plus pegfilgrastim with stage IV non-small cell lung cancer patients

Gunma University0 个研究点目标入组 20 人开始时间: 2017年2月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Symptomatic brain metastases 2. History of bleeding 3. Patient with HIV or HBV or HCV infection 4. Patient with active infection 5. Fever over 38 6. Patient with serious disease condition (severe heart disease, interstitial pneumonia, uncontrollable hypertension, diabetes mellitus, etc) 6. Severe complication (congestive heart failure, arrhythmia, uncontrollable hyper tension, uncontrollable diabetes) 7.Interstitial pneumonia , fibroid lung confirmed by CT. 8.Patient with much ascetic fluid, pleural effusion, cardiac effusion. 9. Patient with active double cancer. (Exclude disease free interval over 5 years and carcinoma in situ) 10. History of severe drug allergy 11.Patient with gastrointestinal perforation within 1 year. 12. Receiving anticoagulant therapy. (Aspirin 325mg or less to allow) 13. Patient thought as of high risk of bleeding (Obvious tumor invasion to main thoracic vessel and cavity) and of thromboembolizm. 14. History of docetaxel or ramcirumab treatment. 15. Considered as unfit to study drug administration by attending doctor according to clinical symptoms or laboratory abnormalities. 16. Considered to be interfere to the agreement or understanding the protocol by attening doctor. 17. Patient with impaired mental status. 18. Pregnancy 19. Other ineligible status judged by attending doctor.

发起方